Data from the present study, as above-described, illustrate that triple cytokine (TNF-α, IL-1β, and IL-6) inhibitions and single cytokine (TNF-α) inhibition can achieve similar therapeutic effects against endotoxemia-induced systemic inflammation and lung injury in the early phase of endotoxemia. This evidence concerns the gene TNF and serum lipopolysaccharide activity.